Acusphere Appoints Mark Leuchtenbergeras President and CEO
-- Co-founder Sherri Oberg to remain as Vice Chairman of the Board --
LEXINGTON, Mass. -- September 16, 2013
Acusphere, Inc. (ACUSD.PK) today announced that Mark Leuchtenberger has been
appointed President, Chief Executive Officer and a Director of the company,
succeeding co-founder Sherri C. Oberg, who will remain on Acusphere’s Board of
Directors as Vice Chairman. Acusphere is currently focused on the development
and regulatory approval of Imagify™ (Perflubutane Polymer Microspheres)
lyophilisate for dispersion for injection, a cardiovascular drug for the
detection of coronary artery disease (CAD), the leading cause of death in the
United States and Europe.
“I am thrilled to join Acusphere at what I believe is an exciting time in the
company’s history,” said Mr. Leuchtenberger. “I look forward to working with
the Acusphere team to complete the final stages of Imagify’s clinical
evaluation and bringing this program forward to market.”
Martyn Greenacre, chairman of Acusphere’s board of directors, said, “We are
delighted to attract an executive of Mark’s caliber and experience to lead
Acusphere through its next phase of growth and development. We are indebted to
Sherri for her dedication and years of success in shepherding Acusphere’s
technology, including Imagify as its lead product candidate, to this pivotal
point. Under Mark’s leadership, we are eager to move ahead with the exciting
opportunities that we believe are available for Acusphere and Imagify.”
Mr. Leuchtenberger most recently served as President, Chief Executive Officer
and a member of the board of directors at Rib-X Pharmaceuticals, bringing
experience in commercial operations, business development and preparing
biopharmaceutical companies for product approval and commercialization. Prior
to joining Rib-X, Mr. Leuchtenberger served as President and Chief Executive
Officer of Targanta Therapeutics Corporation, where he led the company’s
initial public offering in 2007 and its acquisition in 2009. Mr.
Leuchtenberger served as the President and Chief Executive Officer of Therion
Biologics Corporation, a privately held cancer vaccine company. Prior to
Therion, Mr. Leuchtenberger was a senior officer at Biogen Idec Inc., where he
led the Avonex® development and launch in the United States and subsequently
managed North American and international commercial operations. Mr.
Leuchtenberger received his M.B.A. from the Yale School of Management and his
B.A. from Wake Forest University. He is a director and past chairman of the
Massachusetts Biotechnology Council Board of Directors and currently serves
as a trustee for Beth Israel Deaconess Medical Center. He is a co-founder of
Albor Biologics, Inc. and Alvos Therapeutics, Inc.
Added Ms. Oberg, “I share the Board’s genuine excitement and enthusiasm in
welcoming Mark to Acusphere. His exceptional capabilities and expertise,
particularly in leading one of the most successful product launches in biotech
history with Avonex, will be critical in driving forward the commercialization
opportunities for Imagify in the years ahead.”
About Acusphere, Inc.
Acusphere, Inc. (ACUSD.PK) is a specialty pharmaceutical company focused on
the development and regulatory approval of our lead product candidate,
Imagify™ (Perflubutane Polymer Microspheres) lyophilisate for dispersion for
injection. Imagify is a cardiovascular drug for the detection of coronary
artery disease, the leading cause of death in the United States and Europe.
Imagify was created using proprietary technology that enables Acusphere to
control the porosity and size of nanoparticles and microparticles, which were
customized to control the delivery of gas needed for ultrasound myocardial
perfusion assessment. For more information about Acusphere visit the Company's
web site (www.acusphere.com).
MacDougall Biomedical Communications
Douglas MacDougall, 781-235-3060
Bianca Nery, 650-339-7533
Press spacebar to pause and continue. Press esc to stop.